Triiodothyroacetic Acid (TRIAC) Therapy Relieves Hyperthyroid Symptoms, Lowering T4, T3, and Metabolic Rate in Resistance to Thyroid Hormone β
Authors' conclusion
TRIAC therapy in RTHβ relieves hyperthyroid symptoms and lowers resting energy expenditure and circulating thyroid hormones without worsening hepatic hormone resistance or exacerbating cardiac thyromimetic activity. Future clinical trials to determine whether TRIAC treatment alters adverse cardiovascular outcomes in this disorder are warranted.
Study context
- Population
- Adults with resistance to thyroid hormone β (RTHβ); mean age 41 years; 4 males, 4 females
- Participants
- 8 adults
- Exposure
- Post-TRIAC vs baseline
- Outcome
- Hyperthyroid Symptom Scale (HSS) score, serum FT4 and total T3, resting energy expenditure, sleeping heart rate, fasting lipids, glucose and systemic insulin resistance
Methodological detailsreferral center
- Referral center
Main finding
As reported in the abstract
HSS score
Posttreatment
6
Baseline
17.5
P = 0.0014
Observational data: associations, not effects.
Further findings
FT4
P = 0.007
Total T3
P = 0.001
TSH
P = 0.65
Total cholesterol
P = 0.81
Triglyceride
P = 0.44
Mean sleeping heart rate · unchanged
P = 0.56
Plasma NT-proBNP · unchanged
| Outcome | Posttreatment | Baseline | P value |
|---|---|---|---|
| Resting energy expenditure Z-scoreReduced trend | +0.89 | +1.3 | P = 0.38 |
- FT4 — Normalized FT4 and total T3 in 7 of 8 patients
- 7 out of 8
Safety
Tolerability
- TRIAC treatment was well tolerated, with no side effects
Original publication
TRIAC Therapy Relieves Hyperthyroid Symptoms, Lowering T4, T3, and Metabolic Rate in Resistance to Thyroid Hormone β. J Clin Endocrinol Metab. Published 23 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →